Full Year 2023 Net Revenue Increased 80% from 2022 While OPEX Decreased 33% Twirla Demand and Factory Sales Up 121% and 114% Respectively in 2023 vs 2022 Company Completes Pay-Off of Debt Facility in First Quarter 2024 Twirla Demand Expected to Rebound in First Quarter 2024 from Decreased Demand in...
Fourth Quarter 2022 Net Revenue Increased 33% from Third Quarter 2022 While GAAP Quarter-Over-Quarter OPEX Decreased 55% and Non-GAAP OPEX Remained Unchanged Twirla Demand and Factory Sales Up 25% and 30% Respectively in Fourth Quarter 2022 vs Third Quarter 2022 Company Reaffirms Expected Full Year...
Twirla Demand Grows with Cycles Dispensed and Total Prescriptions (TRx) Up 35% and 33% Respectively in Fourth Quarter 2021 vs Third Quarter 2021 New Twirla Connected TV Commercial Expected to launch in April 2022 and Contribute to Further Demand Growth Company Advances Business Plan Designed to...
Perceptive Advisors Increases Credit Facility to $45 million, with $25 million potentially available Achieved Gross Revenue Target In Fourth Quarter 2020, Reflecting Initial Stocking of Twirla® (levonorgestrel and ethinyl estradiol) transdermal system Announces Agreement with Sterling Specialty...
Twirla Delivers Single-Quarter Records for Retail and Non-Retail Demand; Both Channels Up 20% in First Quarter 2023 vs Fourth Quarter 2022 Total OPEX down 8% in First Quarter 2023 vs Fourth Quarter 2022 Company Reaffirms Expected Full Year 2023 Net Revenue in Range of $25-$30 Million Management to...
Twirla Experienced Another Quarter of Double-Digit Demand Growth in First Quarter 2022 Twirla Business Plan Progressing Company Anticipates Future 2022 Quarterly Operating Expenses to be Lower Management to Host Conference Call Today, Thursday, May 12, 2022 at 4:30 p.m....
Prescription Growth Reflects Increasing Demand for Twirla Base of Prescribers Continues to Grow in First Quarter 2021 Growing Distribution Network and Marketing Efforts Expected to Drive Healthcare Provider and Consumer Engagement PRINCETON, N.J., May 04, 2021 (GLOBE NEWSWIRE) -- Agile...
FDA Approved Twirla ® Expected to Reach Wholesalers in the Fourth Quarter of 2020 $93.9 Million in Cash and Cash Equivalents as of March 31, 2020 Management to Host Conference Call at 4:30 PM ET PRINCETON, N.J. , May 05, 2020 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc....
